Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02743078
Title Optune Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors RTOG Foundation, Inc.
Indications

gliosarcoma

giant cell glioblastoma

glioblastoma

high grade glioma

Therapies

Bevacizumab

Age Groups: senior | adult
Covered Countries USA

Facility Status City State Zip Country Details
University of California, San Diego La Jolla California 92093 United States Details
University of California Irvine, Chao Family Comprehensive Cancer Center Orange California 92868 United States Details
Miami Cancer Institute at Baptist Health Miami Florida 33176 United States Details
UF Health Cancer Center at Orlando Health Orlando Florida 32806 United States Details
Emory University Atlanta Georgia 30322 United States Details
Washington University School of Medicine Saint Louis Missouri 63100 United States Details
University of Rochester Rochester New York 14642 United States Details
Cleveland Clinic Foundation Cleveland Ohio 44195 United States Details
Thomas Jefferson University Philadelphia Pennsylvania 19107 United States Details
Medical University of South Carolina Charleston South Carolina 29425 United States Details
Medical College of Wisconsin Milwaukee Wisconsin 53226 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field